These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

196 related items for PubMed ID: 37094049

  • 1.
    ; 2006. PubMed ID: 37094049
    [Abstract] [Full Text] [Related]

  • 2.
    ; 2006. PubMed ID: 38051796
    [Abstract] [Full Text] [Related]

  • 3. Oral berotralstat for the prophylaxis of hereditary angioedema attacks in patients in Japan: A phase 3 randomized trial.
    Ohsawa I, Honda D, Suzuki Y, Fukuda T, Kohga K, Morita E, Moriwaki S, Ishikawa O, Sasaki Y, Tago M, Chittick G, Cornpropst M, Murray SC, Dobo SM, Nagy E, Van Dyke S, Reese L, Best JM, Iocca H, Collis P, Sheridan WP, Hide M.
    Allergy; 2021 Jun; 76(6):1789-1799. PubMed ID: 33247955
    [Abstract] [Full Text] [Related]

  • 4. A review of oral kallikrein inhibitor berotralstat for hereditary angioedema.
    Gao Y, Hwang J, Hwang G, Craig T.
    Drugs Today (Barc); 2022 Feb; 58(2):59-67. PubMed ID: 35188140
    [Abstract] [Full Text] [Related]

  • 5. Oral once-daily berotralstat for the prevention of hereditary angioedema attacks: A randomized, double-blind, placebo-controlled phase 3 trial.
    Zuraw B, Lumry WR, Johnston DT, Aygören-Pürsün E, Banerji A, Bernstein JA, Christiansen SC, Jacobs JS, Sitz KV, Gower RG, Gagnon R, Wedner HJ, Kinaciyan T, Hakl R, Hanzlíková J, Anderson JT, McNeil DL, Fritz SB, Yang WH, Tachdjian R, Busse PJ, Craig TJ, Li HH, Farkas H, Best JM, Clemons D, Cornpropst M, Dobo SM, Iocca HA, Kargl D, Nagy E, Murray SC, Collis P, Sheridan WP, Maurer M, Riedl MA.
    J Allergy Clin Immunol; 2021 Jul; 148(1):164-172.e9. PubMed ID: 33098856
    [Abstract] [Full Text] [Related]

  • 6. Orladeyo (Berotralstat): A Novel Oral Therapy for the Prevention of Hereditary Angioedema.
    Powell J, Piszczatoski C, Rubido E.
    Ann Pharmacother; 2022 Apr; 56(4):488-493. PubMed ID: 34282650
    [Abstract] [Full Text] [Related]

  • 7. Long-term safety and effectiveness of berotralstat for hereditary angioedema: The open-label APeX-S study.
    Farkas H, Stobiecki M, Peter J, Kinaciyan T, Maurer M, Aygören-Pürsün E, Kiani-Alikhan S, Wu A, Reshef A, Bygum A, Fain O, Hagin D, Huissoon A, Jeseňák M, Lindsay K, Panovska VG, Steiner UC, Zubrinich C, Best JM, Cornpropst M, Dix D, Dobo SM, Iocca HA, Desai B, Murray SC, Nagy E, Sheridan WP.
    Clin Transl Allergy; 2021 Jun; 11(4):e12035. PubMed ID: 34161665
    [Abstract] [Full Text] [Related]

  • 8. Population pharmacokinetic modeling and simulations of berotralstat for prophylactic treatment of attacks of hereditary angioedema.
    Mathis A, Sale M, Cornpropst M, Sheridan WP, Ma SC.
    Clin Transl Sci; 2022 Apr; 15(4):1027-1035. PubMed ID: 35212456
    [Abstract] [Full Text] [Related]

  • 9. The synthesis and characterization of the 'research chemical' N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-3-(4-fluorophenyl)-1H-pyrazole-5-carboxamide (3,5-AB-CHMFUPPYCA) and differentiation from its 5,3-regioisomer.
    McLaughlin G, Morris N, Kavanagh PV, Power JD, Twamley B, O'Brien J, Talbot B, Dowling G, Brandt SD.
    Drug Test Anal; 2016 Sep; 8(9):920-9. PubMed ID: 26360802
    [Abstract] [Full Text] [Related]

  • 10. Randomized Trial of the Efficacy and Safety of Berotralstat (BCX7353) as an Oral Prophylactic Therapy for Hereditary Angioedema: Results of APeX-2 Through 48 Weeks (Part 2).
    Wedner HJ, Aygören-Pürsün E, Bernstein J, Craig T, Gower R, Jacobs JS, Johnston DT, Lumry WR, Zuraw BL, Best JM, Iocca HA, Murray SC, Desai B, Nagy E, Sheridan WP, Kiani-Alikhan S.
    J Allergy Clin Immunol Pract; 2021 Jun; 9(6):2305-2314.e4. PubMed ID: 33866032
    [Abstract] [Full Text] [Related]

  • 11.
    ; 2006 Jun. PubMed ID: 29999859
    [Abstract] [Full Text] [Related]

  • 12. Berotralstat (BCX7353) is a novel oral prophylactic treatment for hereditary angioedema: Review of phase II and III studies.
    Manning ME, Kashkin JM.
    Allergy Asthma Proc; 2021 Jul 14; 42(4):274-282. PubMed ID: 34127176
    [Abstract] [Full Text] [Related]

  • 13. Berotralstat in hereditary angioedema due to C1 inhibitor deficiency: first real-world evidence from a Canadian center.
    Srinivasan C, Ritchie B, Adatia A.
    Front Immunol; 2024 Jul 14; 15():1339421. PubMed ID: 38318176
    [Abstract] [Full Text] [Related]

  • 14. [Pharmacological and clinical study results of Berotralstat Hydrochloride for long-term prophylactic treatment of hereditary angioedema].
    Orui S, Nozue H, Kobayashi S, Fujioka M, Maekawa Y.
    Nihon Yakurigaku Zasshi; 2021 Jul 14; 156(6):382-390. PubMed ID: 34719573
    [Abstract] [Full Text] [Related]

  • 15.
    ; 2006 Jul 14. PubMed ID: 29999937
    [Abstract] [Full Text] [Related]

  • 16. Once-Daily Oral Berotralstat for Long-Term Prophylaxis of Hereditary Angioedema: The Open-Label Extension of the APeX-2 Randomized Trial.
    Kiani-Alikhan S, Gower R, Craig T, Wedner HJ, Kinaciyan T, Aygören-Pürsün E, Banerji A, Bernstein JA, Anderson J, Collis P, Johnston DT, Desai B, Tomita D, Gagnon R, Tachdjian R, Soteres DF, Farkas H, Caballero T, McNeil D, Jacobs J, Lumry WR, APeX-2 investigators.
    J Allergy Clin Immunol Pract; 2024 Mar 14; 12(3):733-743.e10. PubMed ID: 38122865
    [Abstract] [Full Text] [Related]

  • 17.
    ; 2006 Mar 14. PubMed ID: 33104317
    [Abstract] [Full Text] [Related]

  • 18.
    ; 2006 Mar 14. PubMed ID: 29999929
    [Abstract] [Full Text] [Related]

  • 19. Prevention of Recurrent Attacks of Hereditary Angioedema (HAE): Berotralstat and Its Oral Bioavailability.
    Diaz-Menindez M, Morgenstern-Kaplan D, Cuervo-Pardo L, Alvarez-Arango S, Gonzalez-Estrada A.
    Ther Clin Risk Manag; 2023 Mar 14; 19():313-317. PubMed ID: 37021074
    [Abstract] [Full Text] [Related]

  • 20. A review of berotralstat for the treatment of hereditary angioedema.
    Farkas H, Balla Z.
    Expert Rev Clin Immunol; 2023 Feb 14; 19(2):145-153. PubMed ID: 36408587
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.